Share
CNBC
Johnson & Johnson’s one-dose coronavirus vaccine is safe and appears to generate a promising immune response in both young and elderly volunteers, according to trial data published Wednesday in the New England Journal of Medicine.
J&J scientists randomly assigned healthy adults between the ages of 18 and 55 and those 65 and older to receive a high or low dose of its vaccine — called Ad26.COV2.S — or a placebo. Some participants in the 18-to-55 age group were also selected to receive a second dose of the vaccine.
Most of the volunteers produced detectable neutralizing antibodies, which researchers believe play an important role in defending cells against the virus, after 28 days, according to the trial data. By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-to-55 age group.
By Berkeley Lovelace Jr. | 13 Jan 2021
RELATED TOPICS:
Trump Says Netanyahu’s Trial Should Be Canceled
14 hours ago
Trump Signals US May Ease Iran Oil Sanction Enforcement to Help Rebuild Country
15 hours ago
CIA Says Intelligence Indicates Iran’s Nuclear Program Severely Damaged
16 hours ago
Upscale Woodward Park Area Apartments Sell for $19 Million
17 hours ago
Trump Administration Orders CA to Strip Trans Athlete of Medals
17 hours ago
Three Mile Island Nuclear Plant Reboot Fast-Tracked to 2027
17 hours ago
Democratic Lawmaker Pleads Not Guilty to Assaulting US Agents at Immigration Center
17 hours ago

Israeli Settlers Raid West Bank Town, Troops Kill 3 Palestinians

West Nile Virus Detected in Mosquitoes in Fresno County

Trump Says Netanyahu’s Trial Should Be Canceled

Trump Signals US May Ease Iran Oil Sanction Enforcement to Help Rebuild Country

CIA Says Intelligence Indicates Iran’s Nuclear Program Severely Damaged
